

1    **Title: An assessment of a rapid SARS-CoV-2 antigen test in Bangladesh**

2    *Zannat Kawser<sup>1</sup>, Mohabbat Hossain<sup>1</sup> Sara Suliman<sup>2</sup>, Shahin Lockman<sup>3,4</sup>, Jesse Gitaka<sup>5,6</sup>, Gama  
3    Bandawe<sup>7</sup>, Redwan Rahmat<sup>1</sup>, Imrul Hasan<sup>1</sup>, Abu Bakar Siddik<sup>1</sup>, Mokibul Hassan Afrad<sup>8</sup>,  
4    Mohammed Ziaur Rahman<sup>8</sup>, Glenn Miller<sup>9</sup>, David R. Walt<sup>9,10,11</sup>, Louise C. Ivers<sup>12,13</sup>, Regina C.  
5    LaRocque<sup>13</sup>, Jason B. Harris<sup>13</sup>, Firdausi Qadri,<sup>8\*</sup>*

6    **Email Adress:**

7    Zannat Kawser- zannatzkawser@gmail.com

8    Mohabbat Hossain- mohabbat@ideshi.org

9    Sara Suliman- ssuliman1@bwh.harvard.edu

10    Shahin Lockman- shahin.lockman@gmail.com

11    Jesse Gitaka- jgitaka@mku.ac.ke

12    Gama Bandawe- gbandawe@must.ac.mw

13    Redwan Rahmat- redwan@ideshi.org

14    Mokibul Hassan Afrad- hassan.afrad@icddrb.org

15    Mohammed Ziaur Rahman –mzrahman@icddrb.org

16    Imrul Hasan- imrul@ideshi.org

17    Abu Bakar Siddik- absiddik@ideshi.org

18    Glenn Miller- GAMILLER@partners.org

19    David R. Walt- dwalt@bwh.harvard.edu

- 20 Louise C. Ivers- LIVERS@mgh.harvard.edu  
21 Regina C. LaRocque- RCLAROCQUE@mgh.harvard.edu  
22 Jason B. Harris- JBHARRIS@mgh.harvard.edu  
23 Firdausi Qadri- fqadri@icddrb.org

24 **Author Affiliation:**

- 25 <sup>1</sup> institute for developing Science and Health initiatives (ideSHi), Dhaka, Bangladesh  
26 <sup>2</sup> Infectious Disease Immunologist, Division of Experimental Medicine, Zuckerberg San  
27 Francisco General Hospital, USA  
28 <sup>3</sup> Division of Infectious Diseases, Brigham and Women's Hospital, Boston MA, USA  
29 <sup>4</sup> Harvard T.H. Chan School of Public Health, Boston MA, USA  
30 <sup>5</sup> Directorate of Research and Innovation, Mount Kenya University, Thika, Kenya  
31 <sup>6</sup> Centre for Malaria Elimination, Mount Kenya University, Thika, Kenya  
32 <sup>7</sup> Biological Sciences Department, Academy of Medical Sciences, Malawi University of Science  
33 and Technology, Thyolo, Malawi  
34 <sup>8</sup> International Center for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh  
35 <sup>9</sup> Mass General Brigham Center for COVID Innovation, Boston, MA  
36 <sup>10</sup> Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA  
37 <sup>11</sup> Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston,  
38 MA  
39 <sup>12</sup> Department of Global Health and Social Medicine, Harvard Medical School, Boston MA,  
40 USA  
41 <sup>13</sup> MGH Center for Global Health, Massachusetts General Hospital, Boston MA, USA

42

43 \*Corresponding Author:

44 Firdausi Qadri

45 Infectious Diseases Division (IDD), icddr,b, 68, Shaheed Tajuddin Ahmed Sarani, Mohakhali,

46 Dhaka 1212, Bangladesh

47 institute for developing Science and Health initiatives (ideSHi), 9 Mohakhali C/A, Dhaka 1212,

48 Bangladesh

49 Phone: 01711595367

50 email: [fqadri@icddrb.org](mailto:fqadri@icddrb.org)

51

52

53 Word count: 4195

54

55 Running head: Rapid SARS-CoV-2 antigen testing in Bangladesh

56

57

58    **Abstract (# 249)**

59    Early detection of SARS-CoV-2 infection is crucial to prevent the spread of the virus. In this study,  
60    we evaluated the performance of a commercial rapid antigen detection test, BD Veritor, and  
61    compared this (and another rapid test, Standard Q) against a gold-standard of nasopharyngeal (NP)  
62    swab tested by reverse transcription-polymerase chain reaction (RT-PCR) in prospectively-  
63    recruited adults in Dhaka, Bangladesh. We compared the sensitivity and specificity of the two  
64    rapid antigen tests against RT-PCR results in 130 symptomatic and 130 asymptomatic adults. In  
65    addition, we evaluated the suitability and ease-of-use of the BD Veritor test in a subsample of  
66    study participants (n=42) and implementers (n=5). The sensitivity of the BD Veritor rapid antigen  
67    test was 70% in symptomatic (95% confidence interval [CI]: 51-85%) and 87% (95% CI: 69-96%)  
68    in asymptomatic individuals with positive SARS-CoV-2 RT-PCR, for overall sensitivity of 78%  
69    (95% CI: 66-88%). The sensitivity of the Standard Q rapid antigen test was 63% (95% CI: 44-  
70    80%) in symptomatic and 73% (95% CI: 54-87%) in asymptomatic individuals. One false positive  
71    in BD Veritor test (specificity 99.5) and no false positive in Standard Q tests were observed  
72    (specificity 100%). The BD Veritor rapid antigen test was 78% sensitive when compared with  
73    RT-PCR irrespective of the cycle threshold (Ct) levels in this evaluation in Bangladesh. The  
74    implementation evaluation data showed good acceptability in the field settings. This warrants large  
75    field evaluation as well as use of the rapid antigen test for quick assessment of SARS-CoV-2 for  
76    containment of epidemics in the country.

77    **Key Words:** SARS-CoV-2, COVID-19, Rapid Antigen Test, RT-PCR, Implementation

78

79    **Introduction:**

80           Rapid antigen detection tests are point-of-care immunochromatographic assays which  
81   detect protein antigens specific to the Severe Acute Respiratory Syndrome of the Coronavirus-2  
82   (SARS-CoV-2) (e.g. nucleocapsid) (1). The ease-of-use and quick turnaround time of such tests  
83   can expand access to testing and decrease delays in diagnosis (2). Furthermore, modeling studies  
84   on SARS-CoV-2 have demonstrated that even if rapid antigen testing is associated with decreased  
85   sensitivity, the accessibility and short turnaround time in reporting results may be advantageous  
86   for decreasing transmission (3). Rapid antigen testing is particularly useful if deployed in the  
87   context of repeated testing over time (4) (5).

88           The performance of the rapid antigen tests has been determined by comparing their  
89   sensitivity and specificity with nucleic acid detection-based reference reaction (6). The current  
90   gold standard for identifying the presence of SARS-CoV-2 is reverse transcription-polymerase  
91   chain reaction (RT-PCR) in samples collected by nasopharyngeal (NP) swab (7). Despite their  
92   high sensitivity, nucleic acid amplification tests are associated with the need for laboratory  
93   processing, high costs, and a longer turnaround from sampling to return of results (8) (9). The NP  
94   swabs are also more challenging and uncomfortable (for patients) to collect than anterior nares  
95   swabs. For this reason, rapid antigen testing is a valuable tool for contact tracing and early  
96   detection of COVID-19 patients to triage for treatment options, especially in settings where RT-  
97   PCR is less available or where follow-up reporting of RT-PCR results is more difficult, and  
98   particularly when anterior nares samples can be used.

99           In this study among asymptomatic and symptomatic adults, we evaluated the performance  
100   (sensitivity/specificity) of two rapid antigen detection tests, the BD Veritor™ (Becton-Dickenson,  
101   USA) and the Standard Q™ (SD-Biosensor, Korea) rapid antigen test, in comparison to NP swab  
102   RT-PCR as the reference standard. The BD Veritor was performed according to the manufacturer's

103 recommendations using an anterior nares swab specimen, while the Standard Q and reference RT-  
104 PCR were performed on nasopharyngeal swab specimens. We also evaluated the performance of  
105 the rapid antigen tests across the spectrum of RT-PCR cycle threshold (Ct) values. Finally, we  
106 assessed the implementation characteristics of the BD Veritor rapid antigen test, including fitness-  
107 for-use in different populations and settings in Bangladesh.

108

109 **Methodology:**

110 ***Study design and participants:*** We enrolled study participants at a triage and sample collection  
111 booth at Kurmitola General Hospital (n=49) as well as at the ideSHi COVID-19 testing facility  
112 (n=211) in Dhaka, Bangladesh. Adults aged 18 and above were eligible for inclusion. For this  
113 analysis, we aimed to enroll 130 symptomatic patients with Covid-19 like symptoms including  
114 fever, cough, headache, sore throat, shortness of breath and fatigue (10) who had their onset of  
115 first symptom within five days, including 100 individuals with negative RT-PCR results and 30  
116 individuals with positive RT-PCR results. In addition, we aimed for a similar target for positive  
117 and negative asymptomatic individuals who presented for routine COVID-19 screening at the  
118 above sites (primarily occupational screening or for known contact with an individual who tested  
119 positive). Written informed consent was obtained from participants. The study was approved by  
120 the Research Review Committee (RRC) and Ethical Review Committee (ERC) of icddr,b  
121 (Protocol no: PR- 20042).

122 ***Specimen collection:*** Nasopharyngeal swab specimens were collected by trained personnel and  
123 placed in a 3-mL tube of viral transport medium (Citoswab, Citotest Labware Manufacturing Co.  
124 Ltd, China) to be used for both Standard Q antigen testing and RT-PCR testing. Anterior nares

125 swab samples were also collected by trained personnel according to the manufacturers'  
126 instructions for BD Veritor. Specifically, the swab provided with the kit was inserted into the  
127 anterior nasal cavity up to 2.5 cm and rolled 5 times along the mucosal surface in both nostrils.  
128 The nasopharyngeal and anterior nares swab specimens were collected simultaneously until the  
129 first 200 individuals with negative RT-PCR results were enrolled in each group (100 symptomatic  
130 and 100 asymptomatic). Thereafter, the anterior nares samples were collected within 24 hours of  
131 the nasopharyngeal specimen until 60 individuals with positive RT-PCR results were accrued (30  
132 symptomatic and 30 asymptomatic).

133 ***RT-PCR on nasopharyngeal swab specimens:*** Viral RNA was extracted from 200 ul of viral  
134 transport media using the magnetic bead based Nextror 32 Fully Automated Nucleic Acid  
135 Extractor (Nucleic Acid Extraction or Purification Kit, Beijing Lepu Medical Technology Co.,  
136 Ltd, China). RT-PCR was carried out using the China CDC primer and probes. In brief, this was  
137 performed in a 20  $\mu$ l reaction volume and each reaction contained extracted RNA, 2x iTaq  
138 Universal Probes Reaction Master Mix (Biorad, CA, USA), iScript Reverse Transcriptase,  
139 the CDC\_ORF1ab and N forward and reverse primers, and probe (11)(12). Specimens were  
140 determined to be positive for SARS-CoV-2 when the ORF1ab and N genes were detected with an  
141 exponential growth curve and a cycle threshold (Ct) value <40, and negative when these genes  
142 could not be detected. The test was considered positive even if one gene was detected. The quality  
143 of the nasopharyngeal specimen extracted was determined by analyzing the curve generated with  
144 the *rnaseP* housekeeping gene.

145 ***Rapid Antigen Testing:*** The rapid tests were performed in accordance with the manufacturer's  
146 instructions. For the BD Veritor assay, the anterior nares swab was inserted into the extraction  
147 reagent tube and mixed in the fluid for a minimum of 15 seconds before discarding. Three drops

148 of the processed specimen were added to the sample well of the device, and incubated for 15  
149 minutes. Following this, the test device was inserted into the Veritor Plus Analyzer (BD) for  
150 reading.

151 For the Standard Q kit, 350 µL of freshly obtained NP swab specimen in viral transport  
152 medium was reconstituted in the extraction buffer supplied by the manufacturer and incubated for  
153 45-50 minutes. For testing, 3 drops (approximately 80 µL) of extracted nasopharyngeal specimen  
154 was applied to the sample well of device, and results were interpreted after 15 minutes, based on  
155 the manufacturer's instructions.

156 ***Assessment of implementation characteristics:*** We surveyed 5 test implementers and 42  
157 participants about the BD Veritor test with a user acceptability and adoption assessment form for  
158 implementers and a feedback form for participants. Five point Likert scale was used for  
159 documenting the level of satisfaction and level of difficulties in addition to the qualitative aspects  
160 in the questionnaire. We also assessed the BD Veritor test in comparison to NP swab RT-PCR  
161 regarding resources to collect and transport samples, and use of Personal Protective Equipment  
162 (PPE) and consumables. We evaluated turnaround times (from the sample collection time until the  
163 result was reported to the participant) for each sample type, assay, and platform from the time of  
164 collection to delivery of results.

165 ***Statistical analysis:*** We calculated the sensitivity and specificity (13) of each rapid test compared  
166 with the NP RT-PCR gold standard, and reported these as a percentage with 95% confidence  
167 intervals (CIs). The sensitivity of both rapid tests (combined) was also analyzed in RT-PCR  
168 positive samples stratified by Ct value >30, 20-30, and <20. The sensitivity of the two rapid tests  
169 was compared and P value was calculated using McNemar's Chi-Square Test. In addition, the

170 comparison of Ct values between symptomatic and asymptomatic individuals was performed using  
171 the Mann-Whitney U test.

172

173 **Results:**

174 We enrolled 262 individuals in this study. Two study participants were subsequently  
175 excluded from the analysis because of incomplete information in the case record forms, resulting  
176 in a study set of 260 individuals. Forty-nine of the symptomatic individuals were enrolled at the  
177 Kurmitola General Hospital, while the remaining 211 participants included in the analysis were  
178 enrolled at the ideSHi testing facility. Demographic characteristics are shown in Table 1. The  
179 median age of the symptomatic individuals was 35 years (range, 18 – 81 years), and 53% were  
180 male. The most common symptom was fever (N=88, 68%), and the median duration (and range)  
181 of symptoms were 3 days (1 to 5 days) in the symptomatic patients. The median age of the  
182 asymptomatic individuals was 33 years (range, 18 – 74), and 81% were male.

183 The sensitivity and specificity of both rapid tests are reported in Table 2. The sensitivity of  
184 the BD Veritor test (78%) was higher than that of the Standard Q test (68%) ( $P=0.041$ ). The  
185 sensitivity of both tests was higher in asymptomatic individuals than in symptomatic individuals.  
186 Only one false positive BD Veritor test was identified in a screened symptomatic individual who  
187 reported a four-day history of cough with no fever, myalgia or loss of smell. No false positive  
188 Standard Q tests were observed.

189 We compared the performance of both rapid antigen tests stratified by the observed Ct  
190 value of the nasopharyngeal RT-PCR. There was no difference in the median Ct value between  
191 the symptomatic and asymptomatic individuals (Figure 1). We also observed no significant  
192 difference ( $P=0.2$  by Mann-Whitney U) in the range of Ct values between the two groups and

193 hence considered such individuals together in the analysis stratified by Ct value (Table 2). For RT-  
194 PCR samples with a Ct < 20 (i.e., those with a high amount of viral genetic material), the sensitivity  
195 of both rapid antigen tests was 100%. For RT-PCR samples with a Ct > 30 (i.e., those with little  
196 viral genetic material), neither rapid antigen test performed well (sensitivity <10%). For RT-PCR  
197 samples with Ct values in the 20-30 range, the sensitivity of the BD Veritor test was 97% (95%  
198 CI: 84-100%), compared with 81% (95% CI: 64-93%) for the Standard Q.

199 We also interviewed a subgroup of participants (n=42) within 24 hours after having  
200 obtained the anterior nares swab for the BD Veritor™ rapid test and asked them about the  
201 suitability of the test, the ease of the sample collection process, the ease of testing, the accuracy of  
202 the test and the turnaround time. Four participants were dissatisfied with the accuracy of the result  
203 by the BD Veritor™, while the remainder of the participants (n=38) were satisfied. All of the 42  
204 interviewees expressed satisfaction with the sample collection process, ease of testing and the 15-  
205 20 minutes turnaround time. The 5 implementers surveyed, each of whom performed more than  
206 50 tests, were satisfied with the kit components, the design of the device, the kit storage conditions,  
207 the quality controls, the time taken for the sequence of steps, the read-out of the results and the  
208 suitability for batch testing along with sequential testing. Based on their experience, testers  
209 estimated more than 100 patients could be tested and results given with the BD Veritor™ kit in  
210 one 8 hour period of a working day.

211

## 212 **Discussion:**

213 We evaluated the performance of the BD Veritor™ rapid antigen test and also compared  
214 with the Standard Q™ antigen test, for detecting SARS-CoV-2 in asymptomatic and symptomatic

215 adults in a real-world, community-based study in Bangladesh between January to April 2021. We  
216 compared both tests to the gold standard RT-PCR performed on a nasopharyngeal swab. We found  
217 the BD Veritor test to be more sensitive (78%) than the Standard Q (68%) in our study population.

218 The sensitivity of both rapid antigen tests was highly dependent on the Ct value of the  
219 specimen evaluated. Both tests were 100% sensitive among individuals with Ct < 20 – those with  
220 high viral loads. These findings are consistent with a study in China that reported 68% sensitivity  
221 and 100% specificity when a Ct value  $\leq 40$  was used as a cut off, as compared with 98% sensitivity  
222 and 100% specificity when Ct value  $\leq 30$  (14).

223 Interestingly, we found that the sensitivity of both the rapid antigen tests was also high  
224 among asymptomatic individuals. . According to the RT-PCR analysis, the national prevalence  
225 rate of COVID-19 in Bangladesh during 26<sup>th</sup> January–15<sup>th</sup> March ranged from 2 to 8% after which  
226 the rate increased to 24% and peaked by beginning of April 2021. Of note, most of the  
227 asymptomatic RT-PCR positive participants were enrolled during the period in which infections  
228 surged, while most of the symptomatic individuals were enrolled prior to the surge. Therefore the  
229 performance of rapid antigen might vary among population groups due to different  
230 epidemiological, geographical conditions and impact of the variants of concern (VOC) circulating  
231 in that time period although no difference has been found until now (5)(15). In Bangladesh, it was  
232 the UK variant, followed by the he South Africa variant predominating in Bangladesh at the time  
233 (<https://www.gisaid.org/>).

234 The use of anterior nares specimens for the BD Veritor rapid antigen test was an added  
235 advantage, and study participants found this test to be more acceptable than the nasopharyngeal  
236 swab. An additional advantage of the BD Veritor testing was that it was carried out directly at the  
237 study site and results were available immediately. In several instances, study participants were

238 informed to isolate themselves until RT-PCR results confirmed the infection. In addition, the  
239 analyzer provided with the kit was able to detect very faint bands on the device barely visible by  
240 the naked eye which reduces the chance of human bias. Inclusion of the positive and negative  
241 controls with other kit components was helpful for quality assessment of the analyzer before use.

242 A limitation of our study is that we compared rapid antigen tests that required different  
243 types of clinical specimens: For the BD Veritor we used anterior nares specimens for rapid test  
244 and a NP sample for PCR; the Standard Q uses only one nasopharyngeal specimen, which is  
245 diluted in viral transport media and used for both PCR and rapid test. If the concentration of the  
246 virus differs between AN and NP swabs, that is in the two sites of the nostril, it can also affect  
247 results. However, we did not see significant discrepancies between the two tests, except when  
248 specimens had high RT-PCR Ct values, indicating low viral loads. In that case both BD Veritor  
249 and the Standard Q failed to detect SARS-CoV-2 virus. Notably, we also found the BD Veritor  
250 rapid antigen test to be more sensitive even though the anterior nares specimen for it were collected  
251 later for the RT-PCR positive individuals.

252 Our study on rapid antigen tests is timely for Bangladesh which is currently experiencing  
253 a second wave and high rates of COVID-19 (16). Point of care tests are urgently needed for health  
254 facilities, travelers, workplaces and the general population, and our findings can help guide the  
255 implementation of these tests in Bangladesh. The BD Veritor test is sensitive enough to detect  
256 cases with high viral load in pre-symptomatic and early symptomatic cases as well as  
257 asymptomatic persons – groups that likely contribute to a significant proportion of transmission  
258 and spread of the disease (17). The patients who test positive by rapid antigen tests can readily be  
259 diagnosed with a minimum turnaround time, which offers the opportunity for early interruption of  
260 transmission through targeted isolation and contact tracing, as infectivity may be high with a Ct<

261 24 or so (18). Persons with negative rapid test who are suspected of having COVID can be tested  
262 by RT-PCR, depending on the epidemiologic context. Our information can provide  
263 implementation guidance when deciding testing strategies in different settings.

264 Many countries are now planning the expanded use of rapid antigen tests, and our results  
265 will provide guidance on their implementation in real-world settings such as that performed our  
266 study site in Bangladesh. Rapid antigen tests will be a critical component of COVID-19 control  
267 for the foreseeable future.

268 **Acknowledgment**

269 We gratefully acknowledge the support of Mass General Brigham (MGB) Center for COVID  
270 Innovation for providing the BD Veritor plus analyzer antigen detection kits and the Massachusetts  
271 General Hospital (MGH) for facilitation of the work. We thank the Bill and Melinda Gates  
272 Foundation for support to icddr,b investigators. icddr,b is grateful to the Governments of  
273 Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted  
274 support. The overall support of Fondation Merieux to ideSHi is acknowledged. We would like to  
275 express our gratitude to the participants for taking part and the field site staff of ideSHi for their  
276 effort to accomplish the work.

277

278    **References:**

- 279    1. Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree  
280       M, Angkasekwainai N, Sutthent R, Puangpunngam N, Tharmviboontri T, Pongraweewan O,  
281       Chuthapisith S, Sirivatanaucksorn Y, Kantakamalakul W, Horthongkham N. 2020. Rapid  
282       SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for  
283       laboratory diagnosis of COVID-19 in Thailand. Virol J 17:1–7.
- 284    2. Eshghifar N, Busheri A, Shrestha R, Beqaj S. 2021. Evaluation of analytical performance  
285       of seven rapid antigen detection kits for detection of SARS-CoV-2 virus. Int J Gen Med  
286       14:435–440.
- 287    3. Kennedy-Shaffer L, Baym M, Hanage WP. 2021. Perfect as the enemy of good: tracing  
288       transmissions with low-sensitivity tests to mitigate SARS-CoV-2 outbreaks. The Lancet  
289       Microbe 2:e219–e224.
- 290    4. Johansson MA, Wolford H, Paul P, Diaz PS, Chen TH, Brown CM, Cetron MS, Alvarado-  
291       Ramy F. 2020. Reducing travel-related SARS-CoV-2 transmission with layered mitigation  
292       measures: Symptom monitoring, quarantine, and testing. medRxiv 1–13.
- 293    5. Holmdahl I, Kahn R, Hay JA, Buckee CO, Mina MJ. 2021. Estimation of Transmission of  
294       COVID-19 in Simulated Nursing Homes With Frequent Testing and Immunity-Based  
295       Staffing. JAMA Netw Open 4:e2110071.
- 296    6. WHO. 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid  
297       immunoassays Interim guidance, 11 September 2020. World Heal Organ 1–9.
- 298    7. Olalekan A, Iwalokun B, Akinloye OM, Popoola O, Samuel TA, Akinloye O. 2020.

- 299        COVID-19 rapid diagnostic test could contain transmission in low- And middle-income  
300        countries. Afr J Lab Med 9:1–8.
- 301        8. Lambert-nicot S, Cuffel A, Pape L, Vauloup-fellous C, Morand-joubert L. 15635.  
302        Evaluation of a Rapid Diagnostic Assay for Detection of. J Clin Microbiol 58:e00977-20.
- 303        9. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, Chen H,  
304        Mubareka S, Gubbay JB, Chan WCW. 2020. Diagnosing COVID-19: The Disease and  
305        Tools for Detection. ACS Nano 14:3822–3835.
- 306        10. Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. 2021. Features, evaluation, and  
307        treatment of coronavirus (COVID-19). StatPearls.
- 308        11. Jung Y, Park GS, Moon JH, Ku K, Beak SH, Lee CS, Kim S, Park EC, Park D, Lee JH,  
309        Byeon CW, Lee JJ, Maeng JS, Kim SJ, Kim S Il, Kim BT, Lee MJ, Kim HG. 2020.  
310        Comparative Analysis of Primer-Probe Sets for RT-qPCR of COVID-19 Causative Virus  
311        (SARS-CoV-2). ACS Infect Dis 6:2513–2523.
- 312        12. CDC. 2020. 2019-Novel Coronavirus ( 2019-nCoV ) Real-time rRT-PCR Panel Primers  
313        and Probes Note : Oligonucleotide sequences are subject to future changes as the 2019-  
314        Novel Coronavirus. Div Viral Dis Centers Dis Control Prev 2.
- 315        13. Smith CJ. 2012. Diagnostic tests (1) - sensitivity and specificity. Phlebology 27:250–251.
- 316        14. Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, Chen J, Pan Y, Chen L, Dan Y, Wang J,  
317        Chen Y, Deng G, Zhou H, Wu Y. 2020. Diagnosis of acute respiratory syndrome  
318        coronavirus 2 infection by detection of nucleocapsid protein. medRxiv  
319        <https://doi.org/10.1101/2020.03.07.20032524>.

- 320 15. Saeed U, Uppal SR, Piracha ZZ, Rasheed A, Aftab Z, Zaheer H, Uppal R. 2021. Evaluation  
321 of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19  
322 national testing strategy. Virol J 18:1–5.
- 323 16. 2021. Experts: Bangladesh's second Covid wave has peaked, situation likely to improve in  
324 May. Dhaka Tribune.
- 325 17. ECDC. 2020. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and  
326 the UK.
- 327 18. Street L. 2016. Predicting infectious SARS-CoV-2 from diagnostic samples 306:0–19.

328 **Tables.**

329

330 **Table 1: Demographic characteristics in different groups of participants.**

<b>Characteristic</b>	<b>Symptomatic</b>		<b>Asymptomatic</b>	
	PCR+(n=30)	PCR-(n=100)	PCR+(n=30)	PCR-(n=100)
Median Age	46.5	32	33.5	33
<b>Sex</b>				
Male	15(50%)	54(54%)	29(96%)	76(76%)
Female	15(50%)	46(46%)	1(4%)	24(24%)
<b>Population category</b>				
Traveler	0 (0%)	0 (0%)	19 (63.3%)	27 (27%)
Student	4 (13.3%)	19 (19%)	2 (6.7%)	1 (1%)
Healthcare worker	3 (10%)	6 (6%)	0 (0%)	2 (2%)
General population	23 (76.6%)	75 (75%)	9 (30%)	70 (70%)

<b>**Symptom spectrum</b>				-	-
Fever alone		1(3.3%)	13 (13%)		
Fever+Cough		4 (13.3%)	7 (7%)		
Fever+Headache		0 (0%)	5 (5%)		
Fever+Cough+Headache		5 (16.7%)	10 (10%)		
Symptoms without fever		7 (23.3%)	35 (35%)		
<b>History of contact</b>		15 (50%)	43 (43%)	7 (23.3%)	3 (3%)
<b>History of regular use of mask</b>		27 (90%)	89 (89%)	24 (80%)	97 (97%)

331 \*Health care worker; \*\*Other symptoms not mentioned indicate sore throat, shortness of breath,  
 332 diarrhea, loss of taste and/or loss of smell, generalized weakness

333 **Table 2: Performance of two rapid antigen detection tests for detection of SARS-CoV-2 in  
 334 comparison to nasopharyngeal RT-PCR.**

Category		*BD + (n)	BD - (n)	BD performance (95% CI)	*Standard Q + (n)	Standard Q - (n)	Standard Q performance (95% CI)
Symptomatic	PCR + (N=30)	21	9	Sensitivity 70% (54-88%)	19	11	Sensitivity 63% (47-83%)
	PCR - (N=100)	1	99	Specificity 99% (95-100%)	0	100	Specificity 100% (69-100%)
Asymptomatic	PCR + (N=30)	26	4	Sensitivity 87% (69-96%)	22	8	Sensitivity 73% (61-92%)
	PCR - (N=100)	0	100	Specificity 100% (69-100%)	0	100	Specificity 100% (69-100%)
<b>Overall sensitivity and specificity (both symptomatic and asymptomatic participants)</b>							
Positive PCR	N = 60	47	13	Sensitivity 78% (66-88%)	41	19	Sensitivity 68% (55-80%)
Negative PCR	N= (200)	1	199	Specificity 99.5% (97-100%)	0	200	Specificity 100% (98-100%)
<b>Combined symptomatic and asymptomatic categorized by RT-PCR cycle threshold (Ct) value</b>							


Ct > 30	N = 13	1	12	Sensitivity 8% (0-36%)	0	13	Sensitivity 0% (0-25%)
Ct 20-30	N = 32	31	1	Sensitivity 97% (84-100%)	26	6	Sensitivity 81% (64-93%)
Ct < 20	N = 15	15	0	Sensitivity 100% (78-100%)	15	0	Sensitivity 100% (78-100%)

335 \*For BD Veritor™ testing kit, anterior nares specimens and for Standard Q, nasopharyngeal

336 specimen were tested based on manufacturer's instruction.

337 **Figures.**

**Ct Value of RT-PCR vs. Rapid Test Results**



338

339 **Figure 1. Comparison of Ct values among symptomatic and asymptomatic study**

340 **participants, and across rapid antigen tests.** There was no significant difference in the median

341 Ct value in PCR positive symptomatic and asymptomatic participants, however, the median Ct

342 values were significantly higher in individuals with false negative rapid antigen tests.